Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Pioneering Self-Encoded Library Strategies for DNA/RNA Binding Proteins

Project description

Next-generation drug screening

Drug target identification is central to the development of new therapies. Researchers leverage diverse technologies to identify compounds that modulate pathways associated with disease. Traditional drug discovery methods such as DNA-encoded libraries face major limitations for proteins involved in DNA and RNA processing because the DNA barcode is chemically and functionally incompatible with the biology of these proteins. To overcome these limitations, the ERC-funded ExSELence project is creating a drug discovery platform that eliminates the need for DNA barcoding. Researchers will validate the platform on ΕΧΟ1, an enzyme involved in DNA replication and repair as well as a promising therapeutic target in cancer.

Objective

The ExSELence project aims to validate and commercialize an innovative drug discovery platform that addresses key limitations in current screening technologies. Traditional approaches to identifying drug candidates, such as DNA-encoded libraries, face significant constraints when screening certain protein targets, particularly those involved in DNA and RNA processing. Our platform eliminates these constraints through a novel barcode-free approach that combines advanced synthesis methods with sophisticated computational analysis. ExSELence will validate the platform's capabilities through a focused study targeting EXO1, a promising therapeutic target in cancer. The project encompasses both technical validation of the platform and development of a comprehensive commercialization strategy. Technical activities will demonstrate the platform's ability to screen large compound libraries efficiently while identifying selective inhibitors. Commercial activities will explore various exploitation paths, from licensing opportunities to spin-off creation. The platform has shown promising initial results, including the successful screening of libraries containing up to one million compounds. The technology is protected by a recently filed patent application and builds on established expertise in combinatorial chemistry, mass spectrometry, and computational analysis. Success in this project would significantly impact drug discovery by making high-throughput screening more accessible to academic laboratories and smaller research institutions. The platform's unique capabilities could accelerate the development of therapeutics for previously challenging targets, particularly in cancer and genetic diseases where DNA- and RNA-binding proteins play crucial roles. The project's outcomes will include validated screening protocols, initial hit compounds for EXO1, and a clear commercialization strategy.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSITEIT LEIDEN
Net EU contribution
€ 150 000,00
Address
RAPENBURG 70
2311 EZ Leiden
Netherlands
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)